Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18550705 | 0.86 | LMNA (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5520049 | 0.83 | ALDH1A1 (0.58) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL27547230 | 0.83 | MAPT (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16119698 | 0.83 | ATM (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4036816 | 0.83 | MAPK1 (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9311982 | 0.82 | ALDH1A1 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15484311 | 0.81 | LMNA (0.69) | MAPTL3MBTL1CYP1A2GAALMNA | |
| SCHEMBL11051530 | 0.81 | GAA (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11261633 | 0.81 | POLB (0.58) | MAPTCYP1A2GAADRD2HTR2A | |
| SCHEMBL17520142 | 0.79 | IRAK4 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114686215-B | Fluorescent material and preparation method and application thereof | TCL科技集团股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117164480-A | Method for preparing cyanamide and mercaptan | 华南理工大学 | 2023-12-05 | — | — | CN | disclosed |
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-20230167270-A1 | ACRYLIC RUBBER COMPOSITION AND RUBBER CROSSLINKED PRODUCT | ZEON CORPORATION (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230129765-A1 | METHOD FOR PRODUCING POLYTHIOETHER COMPOUND | DAICEL CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4108705-A1 | METHOD FOR PRODUCING POLYTHIOETHER COMPOUND | Daicel Corporation (JP) | 2022-12-28 | — | — | EP | disclosed |
| CN-115244127-A | Acrylic rubber composition and rubber crosslinked product | 日本瑞翁株式会社 | 2022-10-25 | — | — | CN | disclosed |
| CN-115135697-A | Process for producing polythioether compound | 株式会社大赛璐 | 2022-09-30 | — | — | CN | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004072068-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1058684-A1 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999045011-A1 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-10 | — | — | WO | disclosed |
| US-4369325-A | ANTIPHLOGISTIC AND DIURETIC ACTIVITY | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1983-01-18 | — | — | US | disclosed |
| US-4326074-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4146647-A | PHENYLAMIDOXIMES, HYPOTENSIVE AGENTS | LABORATOIRE L. LAFON (FR) | 1979-03-27 | — | — | US | disclosed |
| US-4115564-A | Treatment of diarrhea with amidinoureas | WILLIAM H. RORER, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4025652-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | GRIN2D 265/4885GRIN3B 223/4885GRIN1 257/4885 |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | GRIN2D 840/4885GRIN3B 416/4885GRIN1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.